| 8.37 Data as of May 21 |  +0.16 / +1.95%Today’s Change | 6.18 Today|||52-Week Range 8.43 | +18.89% Year-to-Date |
| PDL BioPharma Misses Earnings Ests - Analyst Blog May 13 / Zacks.com |
| Previous close | 8.21 |
| Today’s open | 8.24 |
| Day’s range | 8.22 - 8.37 |
| Volume | 1,939,848 |
| Average volume (3 months) | 1,766,917 |
| Market cap | $1.1B |
| Dividend yield | 7.17% |
| Earnings growth (last year) | +26.09% |
| Earnings growth (this year) | +13.23% |
| Earnings growth (next 5 years) | +17.00% |
| Revenue growth (last year) | +3.45% |
| P/E ratio | 5.3 |
| Price/Sales | 2.63 |
| Price/Book | -- |
| Today’s change | Today’s % change | |
|---|---|---|
| TSROTESARO Inc | +0.25 | +0.70% |
| SRPTSarepta Therapeutics... | -0.48 | -1.29% |
| PBYIPuma Biotechnology I... | -0.68 | -1.81% |
| ACADACADIA Pharmaceutica... | -0.36 | -2.54% |
| Next reporting date | July 31, 2013 |
| EPS forecast (this quarter) | $0.54 |
| Annual revenue (last year) | $374.5M |
| Annual profit (last year) | $211.7M |
| Net profit margin | 56.52% |
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director John Peter McLaughlin |
VP, Chief Financial & Accounting Officer Peter S. Garcia, MBA |
Corporate headquarters Incline Village, Nevada |
.
